STOCK TITAN

Nautilus Biotechnology Inc - NAUT STOCK NEWS

Welcome to our dedicated news page for Nautilus Biotechnology (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nautilus Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nautilus Biotechnology's position in the market.

Rhea-AI Summary
Nautilus Biotechnology, Inc. reported financial results for Q4 and FY 2023, showing progress in developing a single molecule proteome analysis platform. The company's CEO highlighted accomplishments and financial discipline, with operating expenses increasing by 20% to $76.2 million and a net loss of $63.7 million. Cash reserves stood at $264.1 million, with plans for a 25% expense growth in FY 2024 and a platform launch in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
earnings
-
Rhea-AI Summary
Nautilus Biotechnology, Inc. will be participating in the TD Cowen 44th Annual Healthcare Conference, with its management scheduled for a fireside chat on March 6th. The company is known for its single-molecule protein analysis platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
conferences
-
Rhea-AI Summary
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will report financial results for Q4 and full year 2023 on February 28, 2024. The company's management will host a webcast to discuss results, business developments, and outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
earnings
Rhea-AI Summary
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) co-founder and Chief Scientist Parag Mallick, Ph.D., receives the 2024 Gilbert S. Omenn Computational Proteomics Award from US Human Proteome Organization for his career achievements and contributions to bioinformatics analyses and computational methods. Dr. Mallick's work has significantly advanced the field of computational proteomics, enabling global researchers to make breakthroughs in biomedicine. He will present a lecture at the 20th Annual US HUPO conference in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
none
-
Rhea-AI Summary
Nautilus Biotechnology has announced the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development. Dr. Huber brings over 20 years of experience in biotechnology start-ups and has expertise in chemistry and nanoengineering. His appointment will strengthen Nautilus' research and development leadership team as they prepare to launch their single-molecule protein analysis platform next year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Nautilus Biotechnology reports financial results for Q3 2023, with operating expenses of $19.1 million and a net loss of $15.9 million. Cash, cash equivalents, and investments were $275.7 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.4%
Tags
earnings
Rhea-AI Summary
Nautilus Biotechnology to report Q3 financial results on October 31, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
earnings
-
Rhea-AI Summary
Nautilus Biotechnology to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
conferences
-
Rhea-AI Summary
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announces participation in investor conferences and panel discussions on proteomics and genomics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
conferences
Rhea-AI Summary
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported Q2 2023 financial results, highlighting a 23% increase in operating expenses and a net loss of $15.8 million. The company's CEO, Sujal Patel, expressed excitement about progress made in foundational scientific and development goals, with a focus on preparations for a commercial launch in the coming year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
earnings
Nautilus Biotechnology Inc

Nasdaq:NAUT

NAUT Rankings

NAUT Stock Data

367.79M
40.97M
33.65%
49.79%
0.99%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States
Seattle

About NAUT

born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. the extraordinary team at nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.